Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Evolus, Inc. (EOLS)

8.44   0.19 (2.3%) 03-24 16:00
Open: 8.2 Pre. Close: 8.25
High: 8.48 Low: 8.13
Volume: 189,013 Market Cap: 476(M)

Technical analysis

as of: 2023-03-24 4:25:40 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 10.55     One year: 11.35
Support: Support1: 7.92    Support2: 6.59
Resistance: Resistance1: 9.03    Resistance2: 9.72
Pivot: 8.55
Moving Average: MA(5): 8.36     MA(20): 8.67
MA(100): 8.37     MA(250): 9.86
MACD: MACD(12,26): -0.3     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 26.8     %D(3): 27.7
RSI: RSI(14): 44
52-week: High: 14.34  Low: 6.51
Average Vol(K): 3-Month: 552 (K)  10-Days: 405 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ EOLS ] has closed above bottom band by 40.9%. Bollinger Bands are 30.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 8.48 - 8.53 8.53 - 8.57
Low: 8.03 - 8.08 8.08 - 8.12
Close: 8.37 - 8.44 8.44 - 8.51

Company Description

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Headline News

Mon, 13 Mar 2023
Hsbc Holdings PLC Cuts Stake in Evolus, Inc. (NASDAQ:EOLS) - MarketBeat

Mon, 13 Mar 2023
Analysts Set Expectations for Evolus, Inc.'s Q4 2023 Earnings ... - MarketBeat

Sat, 11 Mar 2023
Evolus, Inc. (NASDAQ:EOLS) Q4 2022 Earnings Call Transcript - Yahoo Finance

Wed, 08 Mar 2023
After-Hours Earnings Report for March 8, 2023 : MDB, DADA, VET ... - Nasdaq

Wed, 08 Mar 2023
Evolus Reports Fourth Quarter and Full Year 2022 Results and ... - Business Wire

Wed, 08 Mar 2023
Evolus, Inc. (EOLS) Reports Q4 Loss, Tops Revenue Estimates - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 56 (M)
Shares Float 33 (M)
% Held by Insiders 24.2 (%)
% Held by Institutions 58.1 (%)
Shares Short 2,210 (K)
Shares Short P.Month 2,220 (K)

Stock Financials

EPS -1.33
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.33
Profit Margin (%) -50.1
Operating Margin (%) -38.8
Return on Assets (ttm) -16.6
Return on Equity (ttm) -148.3
Qtrly Rev. Growth 25.8
Gross Profit (p.s.) 1.64
Sales Per Share 2.63
EBITDA (p.s.) -0.96
Qtrly Earnings Growth 0
Operating Cash Flow -85 (M)
Levered Free Cash Flow -54 (M)

Stock Valuations

PE Ratio -6.4
PEG Ratio -1.3
Price to Book value 25.57
Price to Sales 3.2
Price to Cash Flow -5.61

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.